NCT04604496View on ClinicalTrials.gov

STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

PF-06882961 20MG

PF-06882961 in 20 mg oral tablet will be administered on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33136

University of Miami Division of Clinical Pharmacology, Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04604496 - STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT | Biotech Hunter | Biotech Hunter